{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:26Z","timestamp":1792783466570,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"LEO Pharma A\/S","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01869-w","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:01:59Z","timestamp":1787238119000},"page":"4993-5011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of 12\u00a0Months of Tralokinumab in Patients with Atopic Dermatitis"],"prefix":"10.1007","volume":"16","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Juan","family":"Pereyra-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Jarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Andre","family":"Becherel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Festini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Vittrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vinther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1869_CR1","doi-asserted-by":"publisher","unstructured":"Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77:274\u20139.e3. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.019.","DOI":"10.1016\/j.jaad.2017.04.019"},{"key":"1869_CR2","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137. https:\/\/doi.org\/10.1016\/j.anai.2018.07.006.","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"1869_CR3","doi-asserted-by":"publisher","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br J Dermatol. 2021;184:304\u20139. https:\/\/doi.org\/10.1111\/bjd.19580.","DOI":"10.1111\/bjd.19580"},{"key":"1869_CR4","doi-asserted-by":"publisher","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(15)00149-X.","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"1869_CR5","doi-asserted-by":"publisher","unstructured":"Panel AAJADG, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132:274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009.","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"1869_CR6","doi-asserted-by":"publisher","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90:e43\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102.","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"1869_CR7","doi-asserted-by":"publisher","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","DOI":"10.1111\/all.13954"},{"key":"1869_CR8","doi-asserted-by":"publisher","unstructured":"Bunick CG. Biologic therapies targeting type\u00a02 signaling in atopic dermatitis: a comparative review of structural and thermodynamic differences in mechanism of action. J Invest Dermatol. 2025;145:2950\u201363.e4. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1574.","DOI":"10.1016\/j.jid.2025.06.1574"},{"key":"1869_CR9","unstructured":"ADBRY\u00ae (tralokinumab-ldrm). Prescribing information. LEO Pharma A\/S; 2024. https:\/\/mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net\/-\/media\/corporatecommunications\/us\/therapeutic-expertise\/our-product\/adbrypi.pdf?rev=d8ced7cbd6874a6997427ab88a2093e0#page=19. Accessed 2 Jan 2025."},{"key":"1869_CR10","doi-asserted-by":"publisher","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase\u00a0III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","DOI":"10.1111\/bjd.19574"},{"key":"1869_CR11","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase\u00a0III ECZTRA 3 trial. Br J Dermatol. 2021;184:450\u201363. https:\/\/doi.org\/10.1111\/bjd.19573.","DOI":"10.1111\/bjd.19573"},{"key":"1869_CR12","doi-asserted-by":"publisher","unstructured":"Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87:815\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.019.","DOI":"10.1016\/j.jaad.2022.07.019"},{"key":"1869_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1869_CR14","doi-asserted-by":"publisher","unstructured":"Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333. https:\/\/doi.org\/10.1159\/000365390.","DOI":"10.1159\/000365390"},{"key":"1869_CR15","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38:2139\u201348. https:\/\/doi.org\/10.1111\/jdv.20229.","DOI":"10.1111\/jdv.20229"},{"key":"1869_CR16","doi-asserted-by":"publisher","unstructured":"Calabrese L, Cinotti E, D\u2019Onghia M, et al. Effectiveness and safety of tralokinumab in atopic dermatitis: 1-year results from a real-world multicentre study. Acta Derm Venereol. 2025;105:adv42275. https:\/\/doi.org\/10.2340\/actadv.v105.42275.","DOI":"10.2340\/actadv.v105.42275"},{"key":"1869_CR17","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ced\/llaf062","volume":"50","author":"F Barei","year":"2025","unstructured":"Barei F, Calzari P, Pezzolo E, et al. Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study. Clin Exp Dermatol. 2025;50:1373\u201384. https:\/\/doi.org\/10.1093\/ced\/llaf062.","journal-title":"Clin Exp Dermatol"},{"key":"1869_CR18","doi-asserted-by":"publisher","unstructured":"Izu Belloso RM, Julia Manresa M, Martinez Pena N, et al. Real-world clinical practice evaluation of tralokinumab in atopic dermatitis: a 52-week multi-center retrospective study in the Basque Country. J Clin Med. 2025;14:5727. https:\/\/doi.org\/10.3390\/jcm14165727.","DOI":"10.3390\/jcm14165727"},{"key":"1869_CR19","doi-asserted-by":"publisher","unstructured":"Ronnstad ATM, Bunick CG, Chovatiya R, et al. Real-world evidence of tralokinumab effectiveness and safety: a systematic review and meta-analysis. Am J Clin Dermatol. 2025;26:411\u201324. https:\/\/doi.org\/10.1007\/s40257-025-00927-x.","DOI":"10.1007\/s40257-025-00927-x"},{"key":"1869_CR20","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Simpson EL, Armstrong AW, et al. Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23:1\u201311. https:\/\/doi.org\/10.1007\/s40257-021-00639-y.","DOI":"10.1007\/s40257-021-00639-y"},{"key":"1869_CR21","doi-asserted-by":"publisher","unstructured":"Maspero JF, Peters AT, Chapman KR, et al. Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE continuation study. J Allergy Clin Immunol Pract. 2024;12:991\u20137.e6. https:\/\/doi.org\/10.1016\/j.jaip.2023.12.043.","DOI":"10.1016\/j.jaip.2023.12.043"},{"key":"1869_CR22","doi-asserted-by":"publisher","unstructured":"Reich K, Langley RG, Silvestre Salvador JF, et al. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5\u00a0years: an integrated analysis of eight clinical trials. Br J Dermatol. 2026;194:225\u201335. https:\/\/doi.org\/10.1093\/bjd\/ljaf309.","DOI":"10.1093\/bjd\/ljaf309"},{"key":"1869_CR23","doi-asserted-by":"publisher","unstructured":"Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1\u00a0year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase\u00a0III trials. Am J Clin Dermatol. 2023;24:939\u2013952. https:\/\/doi.org\/10.1007\/s40257-023-00806-3.","DOI":"10.1007\/s40257-023-00806-3"},{"key":"1869_CR24","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23:547\u201359. https:\/\/doi.org\/10.1007\/s40257-022-00702-2.","DOI":"10.1007\/s40257-022-00702-2"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01869-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:20Z","timestamp":1791446420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01869-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"April W. Armstrong has served as a research investigator, scientific advisor, or speaker to AbbVie, Alumis, BMS, Galderma, Leo, UCB, J&J, Lilly, Novartis, Sun, Sanofi, Takeda, Regeneron, and Pfizer. Ahmed Ameen has received honorarium as speaker and\/or advisor and\/or principal investigator from AbbVie, Ego Pharma, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and Sanofi. Silvia Ferrucci has been principal investigator and\/or speaker to Almirall, Amgen, AbbVie, Sanofi-Genzyme, Lilly, Novartis, LEO Pharma. Participation in Advisory board of Sanofi Genzyme, AbbVie, Almirall. Jos\u00e9-Juan Pereyra-Rodr\u00edguez is or has been an investigator, advisor, and\/or speaker for AbbVie, Almirall, Galderma, Gebro-Pharma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Michael J. Cork is an investigator and\/or consultant for AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L\u2019Or\u00e9al, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals Inc., and Sanofi. Cory Rubin is a speaker for AbbVie, Amgen, Bayer, BMS, Castle Creek Biosciences, Celgene, Cutanea, Dermavant, DermTech, Galderma, Genentech, Helsinn, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Promius Pharma, Regeneron Pharmaceuticals Inc., Sanofi, Sun Pharma, and UCB; a consultant for AbbVie, Allergan, Amgen, Biofrontera, Castle Creek Biosciences, Celgene, Dermavant, DermTech, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Promius Pharma, Regeneron Pharmaceuticals Inc., Sanofi, and UCB; and an investigator for BMS, Cara Therapeutics, Castle Creek Biosciences, DermTech, Janssen, LEO Pharma, and Sanofi. Abel Jarell has received honoraria and\/or research grants from AbbVie, Almirall, Alumis, Apogee Therapeutics, Arcutis Biotherapeutics, Asana Biosciences, BMS, Castle Biosciences, Concert Pharmaceuticals, Dermavant Sciences, Dermira, Eli Lilly and Company, Foamix Pharmaceuticals, Galderma, Incyte Corporation, Janssen Biotech, LEO Pharma, Novartis, Pfizer, Takeda Pharmaceuticals, UCB, and Vivex Biomedical. Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, LEO Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen, and Boehringer Ingelheim. Pierre-Andre Becherel has received consultant and\/or member of boards and\/or speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB. Jennifer Beecker is an investigator, consultant, advisory board member, speaker for and\/or receives honoraria from AbbVie, Amgen, Apogee, Celgene, CeraVe, Lilly, Galderma, Incyte, Janssen, Johnson and Johnson, La Roche Posay, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Vichy. Teodora Festini, Ida Vittrup, and Frank Vinther are employees and\/or shareholders of LEO Pharma A\/S. Diamant Tha\u00e7i is a lecturer and\/or consultant for AbbVie, Almirall, Amgen, Apogee Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Genzyme, Incyte, Johnson & Johnson, Kyowa Kirin, LEO Pharma, L\u2019Or\u00e9al, Eli Lilly, New Bridge, Novartis, Oruka Therapeutics, Pfizer, Regeneron, Sanofi, Stada, Sun Pharma, Target RWE, Takeda, UCB, and Vichy and received grants from AbbVie, LEO Pharma, and Novartis (paid to institution).","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multi-country study was reviewed by ethics committees at each participating center. The Ethikkommission der Med. Fakult\u00e4t der Universit\u00e4t zu L\u00fcbeck (Ethics Committee at the University of L\u00fcbeck) reviewed and approved this study for the signatory investigator\u2019s center (approval number 21-261). The study was conducted in accordance with Good Pharmacoepidemiology Practice, the Declaration of Helsinki, and any local regulations. All participants provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}